Axogen vs Bioventus
AXGN and BVS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXGN and BVS compare
Axogen is the larger company, worth 3.6 times as much as Bioventus ($3.3B against $913M).
Axogen grew revenue faster over the last twelve months (24.3% versus 3.9% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with −12.0% at Axogen.
Bioventus scores higher on the StockData Score (14 against 11 for Axogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXGN | BVS |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $913M |
| Share price | $55.40 | $10.86 |
| Change, 1 year | 126% | 41.0% |
| Change, 5 years | 468% | −22.5% |
| Beta (5Y) | 1.16 | 0.91 |
| Employees | 622 | 930 |
| StockData Score | ||
| Total score | 11 | 14 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 | 3 |
| Performance score | 3 | 5 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 13.6× |
| P/S | 12.4× | 1.6× (better) |
| P/B | 6.7× | 3.8× (better) |
| EV/EBITDA | – | 14.2× |
| P/FCF | 150× | 10.7× (better) |
| FCF yield | 0.67% | 9.3% (better) |
| Fair value | $23.15 | $16.06 |
| Margin of safety | −139% | 32.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 24.3% (better) | 3.9% |
| Revenue growth, 5Y average | 14.9% (better) | 12.1% |
| Net income growth (TTM) | – | 655% |
| EPS growth (TTM) | – | 627% |
| Profitability | ||
| Gross margin | 74.2% (better) | 68.7% |
| Operating margin | −5.2% | 9.7% (better) |
| Net margin | −12.0% | 9.8% (better) |
| FCF margin | 8.3% | 14.5% (better) |
| Return on equity | −10.3% | 28.2% (better) |
| Return on invested capital | −7.9% | 12.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.96 (better) |
| Net debt / EBITDA | – | 2.44 |
| Interest coverage | −5.7× | – |
| Current ratio | 12.02 (better) | 1.68 |
| Altman Z-score | 37.06 (better) | 2.17 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.32% |
| Shareholder yield | 0.00% (better) | −0.32% |
| Ownership | ||
| Held by institutions | 90.4% | 71.2% |
| Held by insiders | 7.6% | 29.0% |
| Insider net buying, 12 months | −$17.1M | −$181K (better) |
| Short interest, % of float | 12.7% | 5.1% |
Go deeper
- AXGN stock overview
- AXGN income statement
- AXGN valuation and score
- BVS stock overview
- BVS income statement
- BVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.